C12N 2760/20134
Use of virus or viral component as vaccine
Official title: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
C12N2760/20134 (Use of virus or viral component as vaccine) appears on 162 US grants and 197 published applications in this corpus.
Search patents in C12N- Granted patents
- 162
- Published applications
- 197
- Assignees
- 126
- Inventors
- 391
- Latest grant
- 26 May 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 2 | 0 |
| 1978 | 2 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 2 | 0 |
| 1982 | 4 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 2 | 0 |
| 1987 | 6 | 0 |
| 1988 | 3 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 1 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 3 | 0 |
| 2000 | 3 | 0 |
| 2001 | 5 | 2 |
| 2002 | 2 | 4 |
| 2003 | 3 | 7 |
| 2004 | 5 | 4 |
| 2005 | 1 | 3 |
| 2006 | 2 | 7 |
| 2007 | 4 | 3 |
| 2008 | 3 | 6 |
| 2009 | 2 | 5 |
| 2010 | 3 | 5 |
| 2011 | 3 | 9 |
| 2012 | 3 | 5 |
| 2013 | 3 | 8 |
| 2014 | 6 | 9 |
| 2015 | 4 | 9 |
| 2016 | 2 | 8 |
| 2017 | 8 | 13 |
| 2018 | 7 | 7 |
| 2019 | 10 | 12 |
| 2020 | 7 | 13 |
| 2021 | 8 | 10 |
| 2022 | 11 | 16 |
| 2023 | 8 | 12 |
| 2024 | 7 | 9 |
| 2025 | 4 | 8 |
| 2026 | 2 | 3 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Drug delivery composition26 May 2026US 12,636,258 B2Japan Science and Technology Agency
- RNA construct10 Mar 2026US 12,569,548 B2Imperial College Innovations Limited
- Artificial nucleic acid molecules for improved protein expression14 Oct 2025US 12,442,005 B2CureVac AG
- Vaccine composition for preventing rabies, and preparation method thereof15 Jul 2025US 12,357,685 B2Bioapplications Inc.
- Methods of producing and characterizing virus vaccine and virus vaccine composition13 May 2025US 12,297,461 B2Guangzhou Realbenefitspot Pharmaceutical Co., Ltd.
- Lipid nanoparticle mrna vaccines2 Apr 2026US 2026/0090989 A1Acuitas Therapeutics, Inc.
- Compositions and methods for making and using stabilized enveloped viruses by spray-drying and lyophilization2 Apr 2026US 2026/0091106 A1The Regents of the University of Colorado, a body corporate
- Artificial nucleic acid molecules for improved protein expression12 Mar 2026US 2026/0071224 A1CureVac AG
- Lipid nanoparticle mrna vaccines18 Sep 2025US 2025/0288522 A1Acuitas Therapeutics, Inc.
- Compositions and methods for the prevention and treatment of rabies virus infection12 Jun 2025US 2025/0186574 A1Replicate Bioscience, Inc.
Most cited
By later US patents
- Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence128US 5,833,975 AVirogenetics Corporation · 1998
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004
- Pox virus containing DNA encoding a cytokine and/or a tumor associated antigen89US 6,265,189 B1Virogenetics Corporation · 2001
- Replication-defective adenovirus human type 5 recombinant as a vaccine carrier68US 6,019,978 AThe Trustees of the University of Pennsylvania · 2000
- Recombinant poxvirus compositions and methods of inducing immune responses55US 5,942,235 AHealth Research, Inc. · 1999